Table 4 Treatment-related adverse events in HCC patients with Lenvatinib monotherapy
Adverse event | Any grade | Grade I–II | Grade III–V |
|---|---|---|---|
Any adverse event | 37/94.9% | 26/66.7% | 11/28.2% |
Rash | 2/5.1% | 2/5.1% | 0/0.00% |
Diarrhea | 7/18.0% | 6/15.4% | 1/2.6% |
Anemia | 13/33.3% | 10/25.6% | 3/7.7% |
Elevated transaminase | 18/46.2% | 9/23.1% | 9/23.1% |
Hypertension | 3/7.7% | 3/7.7% | 0/0.00% |
Leukopenia | 4/10.3% | 4/10.3% | 0/0.00% |
Hypothyroidism | 6/15.4% | 6/15.4% | 0/0.00% |
Bleeding | 6/15.4% | 6/15.38% | 0/0.00% |
Proteinuria | 12/30.8% | 11/28.2% | 1/2.6% |
Fever | 1/2.6% | 1/2.6% | 0/0.00% |
Fatigue | 7/18.0% | 7/18.0% | 0/0.00% |
Hand-foot skin reaction | 6/15.4% | 6/15.4% | 0/0.00% |
Dysphonia | 1/2.6% | 1/2.6% | 0/0.00% |
Decreased appetite | 3/7.7% | 3/7.7% | 0/0.00% |
Vomitting | 1/2.6% | 1/2.6% | 0/0.00% |